商品名：Lysodren and op-DDD
Mitotane is a cytotoxic agent. Mitotane binds to adrenal proteins and is then converted to a reactive metabolite, which then destroys cells of the zona fasciculata and zona reticularis of the adrenal cortex. Destruction of the adrenal cells is relatively specific and can be complete or partial, depending on the dose used. If only partial destruction of adrenal cortical cells occurs, repeated administration or maintenance doses are needed to suppress hypercortisolemia. Mitotane is a highly lipophilic drug. It is poorly absorbed without food, but oral absorption is enhanced when administered with food or oil.
Mitotane is used primarily to treat pituitary-dependent hyperadrenocorticism (PDH) (Cushing’s disease). It also has been used to treat adrenal tumors. Treatment is initiated with a loading dose, followed by weekly maintenance doses. Other drugs used to suppress cortisol in dogs include ketoconazole, selegiline, and trilostane. Treatment with mitotane has been compared with trilostane and has shown that each drug, although acting through different mechanisms, produces similar survival times in dogs with PDH.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
確認精確成品、來源、調劑狀態與法域 確認物種、診斷、腦垂體或腎上腺疾病型態與治療目標 區分誘導、轉換、維持、再誘導與救援階段 由獸醫師決定基線檢查、內分泌檢驗方法與時點、臨床反應、停藥與再治療規則 建立低腎上腺皮質功能與腎上腺危象的個別化緊急處置計畫 檢視所有併用藥、肝腎狀態、電解質、血糖、神經與胃腸道風險以及繁殖與人員暴露風險
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。